NDAOPHTHALMICSOLUTION/DROPS
Approved
Apr 2016
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
19
Data completeness
7/8 — Comprehensive
BROMSITE (bromfenac) by Fosun Pharma is anti-inflammatory drug (nsaid) that has anti-inflammatory activity. Approved for ocular inflammation, cataract surgery, pain. First approved in 2016.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BROMSITE (bromfenac) is a nonsteroidal anti-inflammatory drug (NSAID) ophthalmic solution administered as eye drops. It reduces postoperative inflammation and ocular pain following cataract surgery by inhibiting cyclooxygenase 1 and 2, thereby blocking prostaglandin synthesis. Prostaglandins mediate intraocular inflammation, blood-aqueous humor barrier disruption, and increased intraocular pressure.
$4MPart D
LOE ApproachingDeclining
2.8 years to LOELate-stage product nearing loss of exclusivity with small team as market consolidates around corticosteroid alternatives.
Mechanism of Action
anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of…
Indications (3)
Worked on BROMSITE at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.